Thrombotic means “blood clots” and Microangiopathy means “small blood vessel problem”. According to the UNC Kidney Center, Thrombotic Microangiopathy (TMA) is a pattern of damage that can occur in the smallest blood vessels inside the body’s vital organs – most commonly the kidney and brain. It is often regarded as TMA and is characterized by micro-angiopathic hemolytic anemia, thrombocytopenia, and micro- thrombi leading to ischemic tissue injury. Though rare, TMA is a life-threatening condition that requires urgent management.
Thrombotic micro-angiopathy is the overarching term used to describe any disease process characterized by thrombocytopenia and micro-angiopathic hemolytic anemia with or without other clinical or laboratory features. These disorders can be divided into primary or secondary forms. Primary thrombotic micro- angiopathies (TTP and HUS) occur spontaneously with no associated underlying cause. Secondary forms occur in the context of pregnancy, autoimmune disease, malignancy, bone marrow transplantation, or the use of certain medications, and treatment should be aimed at correcting the underlying cause.
DelveInsight’s “Thrombotic Microangiopathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Thrombotic Microangiopathy, historical and forecasted epidemiology as well as the Thrombotic Microangiopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Thrombotic Microangiopathy Market Report:
- According to the National Organization for Rare Disorders (n.d.), Thrombotic Microangiopathy is more common in women with a 2:1 female to male predominance
- Researchers estimate that around 3.1 million people in the United States suffer from Thrombotic Microangiopathy
- In the case of TMA with autoimmune diseases, CAPS accounts for 14% of cases and SLE for 8–15% of TMA
- With reference to various studies, it is found that the occurrence of TMA and its other types is more common in females compared to males
Request a sample for the Report: https://www.delveinsight.com/sample-request/thrombotic-microangiopathy-tma-market
The symptoms of Thrombotic Microangiopathy include-
- Nose Bleeding
- Decreased Urine
- Body Fatigue
- Swollen Legs
- High Blood Pressure
- Low Platelet Count
Thrombotic Microangiopathy Market
The dynamics of the Thrombotic Microangiopathy market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Defibrotide, Pegcetacoplan, Ravulizumab, and others during the forecasted period 2019-2032.
Learn more by requesting for sample @Thrombotic Microangiopathy Market Landscape
- nomacopan (rVA576)
- Apellis Pharmaceuticals
- Alexion Pharmaceuticals
- AKARI Therapeutics
Click here to read more about Thrombotic Microangiopathy Market Outlook 2032
Thrombotic Microangiopathy Pipeline
"Thrombotic Microangiopathy Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into present clinical development scenarios and growth prospects across the Thrombotic Microangiopathy market. A detailed picture of the Thrombotic Microangiopathy pipeline landscape is provided, which includes the disease overview and Thrombotic Microangiopathy treatment guidelines.
Thrombotic Microangiopathy Epidemiology
DelveInsight's 'Thrombotic Microangiopathy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical, and forecasted Thrombotic Microangiopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight